| Literature DB >> 28953262 |
Zhongyu Xu1,2, Haibin Zhou3, Lin Lei4, Hongyu Li5, Weiye Yu6, Zhen Fu7, Nanjin Wu8, Ji Peng9, Ping Yin10.
Abstract
Cancer is a serious public health issue and the leading cause of death around the world. This article aimed to estimate the cancer incidence and the trend in standardized cancer incidence in Shenzhen, Guangdong province, South China during 2001-2015 by analyzing the cancer data of the population-based cancer registry in Shenzhen. Data were collected from the cancer registry in Shenzhen, which was conducted during 2001-2015. In this registry, the crude incidence rates, age-specific incidence rates, age-standardized incidence rates and cumulative incidence rates were calculated in every five years. Trends for standardized incidence rates of cancers were analyzed by using the joinpoint regression analysis. In total, 33,374.3 thousand person-years (17,593.9 thousand for males and 15,780.4 thousand for females) were monitored over this time period. The number of new cancer cases during 2001-2015 was 59,218 (30,144 and 29,074 for males and females, respectively). The crude incidence during 2001-2005 was 136.44 per 100,000 persons, while the age-standardized rates by Chinese standard population (ASR-China) and by world standard population (ASR-world) were 165.13 and 212.48 per 100,000 persons, respectively. The crude incidence during 2006-2010 was 179.01 per 100,000 persons, while the ASR-China and ASR-world were 168.08 and 214.44 per 100,000 persons, respectively. The crude incidence during 2011-2015 was 196.53 per 100,000 persons, while the ASR-China and ASR-world were 171.44 and 219.99 per 100,000 persons, respectively. During 2001 and 2015, the joinpoint regression analysis showed that the ASR-China of cancer had an overall increase of 0.96% per year and 0.84% per year for males and females respectively, although both of these values (males and females) were non-significant increases. The leading cancer types during 2011-2015 were lung, colorectal, thyroid gland, breast, liver, stomach, cervix, nasopharynx, leukemia and lymphoma. For males, the top five common cancers were lung, liver, colorectal, stomach and thyroid gland. For females, the top five common cancers were breast, thyroid gland, lung, colorectal and cervix. The results of this study showed a heavy cancer burden among the population of Shenzhen, China. Future researches of the etiology and prevention of cancers should be planned in order to reduce the incidence associated with cancers in the future.Entities:
Keywords: Shenzhen; cancer registry; epidemiology; incidence; malignancy
Mesh:
Year: 2017 PMID: 28953262 PMCID: PMC5664638 DOI: 10.3390/ijerph14101137
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Registered population coverage in Shenzhen city during 2001–2015 (×103 persons).
| Year | Total | Male | Female |
|---|---|---|---|
| 2001 | 1284.8 | 673.4 | 611.4 |
| 2002 | 1357.5 | 715.3 | 642.2 |
| 2003 | 1452.0 | 766.6 | 685.4 |
| 2004 | 1580.3 | 836.5 | 743.8 |
| 2005 | 1735.4 | 921.4 | 814.0 |
| 2006 | 1893.8 | 1007.2 | 886.6 |
| 2007 | 2046.1 | 1088.7 | 957.4 |
| 2008 | 2202.3 | 1171.0 | 1031.3 |
| 2009 | 2347.6 | 1248.0 | 1099.6 |
| 2010 | 2462.4 | 1308.0 | 1154.5 |
| 2011 | 2594.7 | 1374.1 | 1220.6 |
| 2012 | 2777.6 | 1463.8 | 1313.8 |
| 2013 | 2990.5 | 1565.4 | 1425.1 |
| 2014 | 3213.4 | 1670.5 | 1543.0 |
| 2015 | 3436.0 | 1784.1 | 1651.9 |
| total | 33,374.3 | 17,593.9 | 15,780.4 |
Quality evaluation of cancers of every site in Shenzhen cancer registration during 2001–2015.
| Cancer | ICD-10 | MV (%) | DCO (%) | M/I |
|---|---|---|---|---|
| Oral & pharynx | C00–C10, C12–C14 | 89.03 | 0.68 | 0.12 |
| Nasopharynx | C11 | 81.56 | 1.47 | 0.12 |
| Esophagus | C15 | 78.99 | 1.45 | 0.19 |
| Stomach | C16 | 81.70 | 1.87 | 0.20 |
| Colorectal | C18–C21 | 86.82 | 1.03 | 0.15 |
| Liver | C22 | 31.74 | 2.69 | 0.30 |
| Gallbladder & extrahepatic bile duct | C23–C24 | 46.80 | 1.88 | 0.29 |
| Pancreas | C25 | 34.62 | 6.00 | 0.36 |
| Lung | C33–C34 | 55.28 | 2.74 | 0.28 |
| Bone | C40–C41 | 63.67 | 1.13 | 0.21 |
| Breast | C50 | 93.00 | 0.50 | 0.05 |
| Cervix | C53 | 93.09 | 0.68 | 0.06 |
| Uterus | C54–C55 | 93.98 | 0.77 | 0.06 |
| Ovary | C56 | 83.94 | 1.27 | 0.14 |
| Prostate | C61 | 73.13 | 1.31 | 0.15 |
| Kidney & unspecified urinary organs | C64–C66, C68 | 71.88 | 1.39 | 0.11 |
| Bladder | C67 | 82.24 | 0.54 | 0.09 |
| Brain & CNS (Central nervous system) | C70–C72 | 59.97 | 2.11 | 0.17 |
| Thyroid gland | C73 | 96.00 | 0.09 | 0.01 |
| Lymphoma | C81–C85, C88, C90, C96 | 91.74 | 1.79 | 0.19 |
| Leukemia | C91–C95 | 95.36 | 2.71 | 0.20 |
| Total | ALL | 75.02 | 1.61 | 0.16 |
MV% = percentage of morphological verification; DCO% = percentage of cancer cases identified with death certification only; and M/I = mortality to incidence ratio.
The incidence rate of cancers (ICD-10:C00-C97) registered in Shenzhen during 2001–2015.
| Year | Sex | No. of Cases | Incidence Rate (1/105) | ASR-China † (1/105) | ASR-World § (1/105) | Cumulative Rate 0–74 Years Old (%) |
|---|---|---|---|---|---|---|
| 2001–2005 | both | 10,110 | 136.44 | 165.13 | 212.48 | 25.39 |
| male | 5404 | 138.10 | 173.65 | 227.60 | 27.93 | |
| female | 4706 | 134.58 | 159.16 | 200.77 | 22.84 | |
| 2006–2010 | both | 19,605 | 179.01 | 168.08 | 214.44 | 24.82 |
| male | 10,087 | 173.23 | 179.31 | 234.42 | 27.56 | |
| female | 9518 | 185.56 | 159.03 | 198.21 | 22.17 | |
| 2011–2015 | both | 29,503 | 196.53 | 171.44 | 219.99 | 24.23 |
| male | 14,653 | 186.47 | 182.70 | 241.15 | 26.70 | |
| female | 14,850 | 207.56 | 164.10 | 205.50 | 22.13 |
† = age-standardized incidence rate (China population, 1982); and § = age-standardized incidence rate (Segi’s population).
Gender- and age-specific incidence characteristics of all cancer cases registered in Shenzhen during 2001–2015.
| Age Groups (Years) | 2001–2005 Incidence Rate (1/105) | 2006–2010 Incidence Rate (1/105) | 2011–2015 Incidence Rate (1/105) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Both | Male | Female | Both | Male | Female | Both | Male | Female | |
| 0– | 8.60 | 9.98 | 6.82 | 14.83 | 15.76 | 13.74 | 12.51 | 11.05 | 14.13 |
| 1– | 18.91 | 18.86 | 18.68 | 18.01 | 23.33 | 11.70 | 20.15 | 22.96 | 17.09 |
| 5– | 13.58 | 14.81 | 11.59 | 18.14 | 19.84 | 15.99 | 15.74 | 18.18 | 12.94 |
| 10– | 12.65 | 11.98 | 13.40 | 13.24 | 11.82 | 15.09 | 13.99 | 15.91 | 11.61 |
| 15– | 6.95 | 9.61 | 5.69 | 25.60 | 22.76 | 29.23 | 20.44 | 17.04 | 25.36 |
| 20– | 14.70 | 16.37 | 13.99 | 31.95 | 22.88 | 43.20 | 42.19 | 29.04 | 62.04 |
| 25– | 28.59 | 19.22 | 40.88 | 53.38 | 39.03 | 69.98 | 51.19 | 37.63 | 66.34 |
| 30– | 74.52 | 49.05 | 106.40 | 82.74 | 62.97 | 102.88 | 96.13 | 74.56 | 116.32 |
| 35– | 137.20 | 111.60 | 165.77 | 132.79 | 103.33 | 163.06 | 107.05 | 79.81 | 134.25 |
| 40– | 229.61 | 166.60 | 308.00 | 173.09 | 137.50 | 212.68 | 168.68 | 118.75 | 224.66 |
| 45– | 253.30 | 206.94 | 313.92 | 216.03 | 172.14 | 269.72 | 261.95 | 200.55 | 332.35 |
| 50– | 427.03 | 391.78 | 468.24 | 424.40 | 389.61 | 466.93 | 436.49 | 389.36 | 490.78 |
| 55– | 605.54 | 615.55 | 596.29 | 577.12 | 606.74 | 547.31 | 570.68 | 616.27 | 526.85 |
| 60– | 752.68 | 833.20 | 664.08 | 734.22 | 831.75 | 637.89 | 831.47 | 978.78 | 695.61 |
| 65– | 1214.37 | 1516.53 | 898.73 | 1116.96 | 1374.09 | 877.65 | 1070.32 | 1386.22 | 795.42 |
| 70– | 1290.88 | 1604.85 | 944.17 | 1346.36 | 1695.04 | 969.92 | 1140.06 | 1357.17 | 915.46 |
| 75– | 1333.62 | 1738.17 | 952.10 | 1482.23 | 1991.92 | 965.41 | 1654.14 | 2119.49 | 1193.65 |
| 80– | 1306.35 | 1680.00 | 1026.98 | 1757.22 | 2335.09 | 1284.95 | 2044.78 | 2850.08 | 1389.61 |
| 85+ | 880.02 | 1261.90 | 713.76 | 1244.98 | 1892.51 | 930.56 | 1599.95 | 2539.70 | 1136.80 |
Figure 1Gender- and age-specific incidence characteristics of all cancer cases registered in Shenzhen during 2001–2005.
Figure 2Gender- and age-specific incidence characteristics of all cancer cases registered in Shenzhen during 2006–2010.
Figure 3Gender- and age-specific incidence characteristics of all cancer cases registered in Shenzhen during 2011–2015.
Crude incidences of the top 10 cancers in Shenzhen during 2001–2015.
| Sex | Rank | 2001–2005 | 2006–2010 | 2011–2015 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Site | Incidence (1/105) | Proportion (%) | Site | Incidence (1/105) | Proportion (%) | Site | Incidence (1/105) | Proportion (%) | Percent Change in Incidence vs. 2001–2005 | ||
| both | 1 | Lung | 19.92 | 14.60 | Lung | 25.03 | 13.98 | Lung | 27.15 | 13.82 | 36.30% |
| 2 | Colorectal | 15.48 | 11.35 | Colorectal | 19.80 | 11.06 | Colorectal | 22.69 | 11.55 | 46.58% | |
| 3 | Liver | 15.37 | 11.27 | Breast | 18.63 | 10.41 | Thyroid gland | 21.01 | 10.69 | 348.93% | |
| 4 | Breast | 13.51 | 9.90 | Liver | 18.08 | 10.10 | Breast | 21.00 | 10.68 | 55.44% | |
| 5 | Stomach | 9.89 | 7.25 | Stomach | 10.62 | 5.93 | Liver | 16.89 | 8.60 | 9.89% | |
| 6 | Nasopharynx | 7.84 | 5.75 | Thyroid gland | 8.94 | 4.99 | Stomach | 10.52 | 5.36 | 6.37% | |
| 7 | Leukemia | 5.72 | 4.19 | Cervix | 8.91 | 4.98 | Cervix | 6.94 | 3.53 | 51.53% | |
| 8 | Thyroid gland | 4.68 | 3.43 | Nasopharynx | 7.70 | 4.30 | Nasopharynx | 6.84 | 3.48 | –12.76% | |
| 9 | Cervix | 4.58 | 3.35 | Leukemia | 7.04 | 3.93 | Leukemia | 6.52 | 3.32 | 13.99% | |
| 10 | Esophagus | 4.21 | 3.09 | Lymphoma | 5.64 | 3.15 | Lymphoma | 6.52 | 3.32 | 59.41% | |
| male | 1 | Lung | 25.25 | 18.28 | Lung | 30.72 | 17.74 | Lung | 33.28 | 17.85 | 31.80% |
| 2 | Liver | 23.25 | 16.84 | Liver | 27.27 | 15.74 | Liver | 25.71 | 13.79 | 10.58% | |
| 3 | Colorectal | 16.46 | 11.92 | Colorectal | 22.36 | 12.91 | Colorectal | 25.40 | 13.62 | 54.31% | |
| 4 | Stomach | 11.93 | 8.64 | Stomach | 12.24 | 7.07 | Stomach | 12.27 | 6.58 | 2.85% | |
| 5 | Nasopharynx | 11.32 | 8.20 | Nasopharynx | 10.66 | 6.16 | Thyroid gland | 11.44 | 6.14 | 576.92% | |
| 6 | Leukemia | 6.11 | 4.42 | Leukemia | 7.88 | 4.55 | Nasopharynx | 9.39 | 5.04 | –17.05% | |
| 7 | Esophagus | 5.72 | 4.15 | Lymphoma | 6.25 | 3.61 | Prostate | 8.55 | 4.59 | 161.47% | |
| 8 | Lymphoma | 4.17 | 3.02 | Prostate | 5.94 | 3.43 | Leukemia | 7.94 | 4.26 | 29.95% | |
| 9 | Bladder | 3.99 | 2.89 | Esophagus | 5.86 | 3.38 | Lymphoma | 7.32 | 3.92 | 75.54% | |
| 10 | Brain& CNS | 3.58 | 2.59 | Bladder | 5.15 | 2.97 | Bladder | 5.70 | 3.06 | 42.86% | |
| female | 1 | Breast | 28.57 | 21.23 | Breast | 39.42 | 21.24 | Breast | 43.72 | 21.06 | 53.03% |
| 2 | Colorectal | 14.38 | 10.69 | Cervix | 19.03 | 10.25 | Thyroid gland | 31.52 | 15.19 | 292.04% | |
| 3 | Lung | 13.96 | 10.37 | Lung | 18.56 | 10.00 | Lung | 20.42 | 9.84 | 46.28% | |
| 4 | Cervix | 9.69 | 7.20 | Colorectal | 16.88 | 9.10 | Colorectal | 19.72 | 9.50 | 37.13% | |
| 5 | Thyroid gland | 8.04 | 5.97 | Thyroid gland | 14.33 | 7.72 | Cervix | 14.56 | 7.02 | 50.03% | |
| 6 | Stomach | 7.61 | 5.65 | Stomach | 8.77 | 4.73 | Stomach | 8.61 | 4.15 | 13.14% | |
| 7 | Liver | 6.55 | 4.87 | Ovary | 7.93 | 4.28 | Ovary | 8.34 | 4.02 | 62.89% | |
| 8 | Leukemia | 5.29 | 3.93 | Liver | 7.64 | 4.12 | Uterus | 7.60 | 3.66 | 165.73% | |
| 9 | Ovary | 5.12 | 3.80 | Leukemia | 6.08 | 3.28 | Liver | 7.21 | 3.47 | 10.08% | |
| 10 | Lymphoma | 4.00 | 2.97 | Uterus | 5.24 | 2.83 | Lymphoma | 5.65 | 2.72 | 41.25% | |
Trend analysis for the top 10 cancer types in 2011–2015 in Shenzhen during 2001–2015 (males).
| ASR-China (1/105) † | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | All cancers | Lung | Liver | Colorectal | Stomach | Thyroid Gland | Nasopharynx | Prostate | Leukemia | Lymphoma | Bladder |
| 2001 | 145.79 | 31.75 | 21.57 | 20.15 | 13.50 | 0.95 | 10.64 | 2.76 | 5.23 | 4.24 | 4.69 |
| 2002 | 159.91 | 31.54 | 28.15 | 19.51 | 16.09 | 1.53 | 12.02 | 2.94 | 7.82 | 3.99 | 3.36 |
| 2003 | 185.98 | 39.90 | 29.45 | 19.15 | 17.17 | 1.59 | 11.39 | 5.52 | 8.46 | 5.55 | 4.25 |
| 2004 | 171.20 | 31.68 | 27.79 | 22.60 | 17.17 | 1.85 | 11.42 | 5.12 | 7.18 | 4.95 | 5.36 |
| 2005 | 196.65 | 38.37 | 30.88 | 24.42 | 15.62 | 2.12 | 13.10 | 6.33 | 6.45 | 6.61 | 7.70 |
| 2006 | 154.95 | 27.99 | 21.36 | 21.80 | 12.20 | 2.21 | 8.77 | 5.57 | 7.71 | 6.10 | 3.70 |
| 2007 | 183.18 | 38.08 | 27.45 | 23.29 | 13.21 | 3.19 | 9.28 | 6.48 | 7.17 | 5.44 | 5.63 |
| 2008 | 180.45 | 33.18 | 27.31 | 21.84 | 11.77 | 2.77 | 8.12 | 7.12 | 9.66 | 6.08 | 6.52 |
| 2009 | 175.32 | 32.78 | 26.11 | 25.25 | 14.55 | 4.30 | 8.45 | 7.09 | 8.24 | 6.41 | 4.93 |
| 2010 | 197.65 | 38.91 | 26.45 | 25.92 | 13.58 | 3.50 | 8.97 | 8.29 | 8.96 | 9.10 | 6.13 |
| 2011 | 168.78 | 34.32 | 21.75 | 23.17 | 11.53 | 2.97 | 7.22 | 8.85 | 8.85 | 5.13 | 5.98 |
| 2012 | 206.81 | 36.44 | 30.43 | 29.02 | 16.22 | 6.06 | 10.04 | 10.34 | 9.46 | 7.92 | 6.11 |
| 2013 | 185.53 | 35.73 | 24.89 | 26.13 | 11.36 | 10.05 | 6.58 | 9.15 | 8.26 | 7.16 | 5.92 |
| 2014 | 166.05 | 32.47 | 20.41 | 22.44 | 9.57 | 9.20 | 5.66 | 9.28 | 7.18 | 8.15 | 4.88 |
| 2015 | 186.72 | 37.91 | 21.98 | 25.59 | 13.85 | 10.60 | 7.00 | 10.97 | 8.73 | 7.84 | 5.58 |
| APC (%) ‡ | 0.96 | 0.57 | –1.05 | 1.92 * | –2.06 * | 16.95 * | –4.38 * | 41.70 * (2001–2003) | 1.96 * | 4.36 * | 2.08 |
| 6.68 * (2003–2015) | |||||||||||
† = age-standardized incidence rate (China population, 1982); ‡ = annual percent change of ASR-China; and * The APC is significantly different from zero at alpha = 0.05.
Trend analysis for the top 10 cancer types in 2011–2015 in Shenzhen during 2001–2015 (females).
| ASR-China (1/105) † | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | All cancers | Breast | Thyroid Gland | Lung | Colorectal | Cervix | Stomach | Ovary | Uterus | Liver | Lymphoma |
| 2001 | 125.87 | 27.98 | 5.16 | 16.57 | 15.96 | 5.36 | 8.10 | 3.71 | 2.64 | 5.14 | 2.87 |
| 2002 | 152.52 | 33.22 | 8.06 | 17.35 | 13.98 | 7.74 | 12.42 | 4.04 | 3.15 | 9.19 | 5.38 |
| 2003 | 166.99 | 33.17 | 7.01 | 20.52 | 20.60 | 9.25 | 7.28 | 6.29 | 3.34 | 8.79 | 5.65 |
| 2004 | 159.73 | 27.75 | 8.34 | 16.65 | 21.40 | 11.43 | 11.46 | 6.46 | 3.16 | 7.59 | 4.54 |
| 2005 | 182.29 | 37.37 | 9.46 | 20.04 | 18.77 | 13.29 | 7.64 | 8.61 | 5.38 | 10.07 | 5.73 |
| 2006 | 140.33 | 23.70 | 7.70 | 14.62 | 15.10 | 13.44 | 7.82 | 4.30 | 3.67 | 7.72 | 3.84 |
| 2007 | 158.17 | 26.05 | 11.69 | 20.30 | 14.37 | 12.87 | 8.74 | 6.43 | 4.59 | 6.38 | 4.74 |
| 2008 | 167.89 | 28.15 | 11.45 | 19.78 | 14.71 | 15.41 | 7.54 | 8.39 | 5.19 | 7.84 | 4.65 |
| 2009 | 157.05 | 30.10 | 11.37 | 16.56 | 15.44 | 11.18 | 8.11 | 7.01 | 3.73 | 7.45 | 4.69 |
| 2010 | 168.08 | 35.87 | 11.04 | 18.82 | 18.59 | 11.29 | 7.49 | 7.99 | 5.69 | 7.25 | 6.36 |
| 2011 | 151.15 | 25.51 | 15.71 | 17.90 | 15.07 | 8.96 | 7.53 | 7.04 | 6.70 | 5.22 | 5.58 |
| 2012 | 179.07 | 30.30 | 20.23 | 20.80 | 17.71 | 13.54 | 8.58 | 7.75 | 6.08 | 6.80 | 5.42 |
| 2013 | 170.32 | 31.91 | 23.51 | 18.53 | 18.41 | 10.46 | 5.36 | 8.40 | 5.54 | 6.98 | 4.68 |
| 2014 | 153.41 | 29.36 | 25.65 | 14.75 | 14.33 | 8.59 | 6.45 | 7.35 | 5.01 | 5.90 | 5.36 |
| 2015 | 166.40 | 33.42 | 26.40 | 17.82 | 17.72 | 8.21 | 6.67 | 5.64 | 6.65 | 6.38 | 5.07 |
| APC (%) ‡ | 0.84 | 0.17 | 11.38 * | –0.04 | –0.22 | 26.38 * (2001–2005) | –2.88 * | 3.42 * | 5.78 * | –1.66 | 1.67 |
| –4.80 * (2005–2015) | |||||||||||
† = age-standardized incidence rate (China population, 1982); ‡ = annual percent change of ASR-China; and * The APC is significantly different from zero at alpha = 0.05.
Figure 4Trend analysis for overall cancer for males and females in Shenzhen.
Figure 5Trend analysis for the top 10 cancer types in 2011–2015 for males in Shenzhen.
Figure 6Trend analysis for the top 10 cancer types in 2011–2015 for females in Shenzhen.